Dealing Fentanyl Legally: What Safe Supply Really Means in Canada

Did you know that there is a Canadian government program that provides prescribed opioids, stimulants, and benzodiazepines to individuals using illicit drugs? While providing pharmaceutical-grade drugs may seem counterintuitive at first glance, the program’s primary goal is to combat the toxic drug crisis, which currently claims an average of 15 Canadian lives each day due to opioid toxicity (H. Canada 2021a; P. H. A. of Canada 2019). This initiative aims to directly reduce those fatalities by offering safer, regulated alternatives (H. Canada 2021a). The program operates on a medicalized harm-reduction model (Chang et al. 2023). Instead of relying on traditional addiction treatments that require immediate abstinence, healthcare providers prescribe a pharmaceutical-grade opioid, most commonly Dilaudid (hydromorphone), as a regulated alternative to toxic street fentanyl (Karamouzian et al. 2023; Roberts and Humphreys 2023; Young et al. 2022). 

This transition is crucial because illicit fentanyl is a potent full agonist at the μ-opioid receptor (Garnett et al. 2026). Fentanyl binds to the μ-opioid receptor with high intrinsic efficacy, triggering intense intracellular signalling cascades that suppress pain, induce euphoria, and directly shut down the respiratory center in the brainstem (Herman et al. 2024; Theriot et al. 2026; Dhaliwal and Gupta 2023; Saunders et al. 2022). Fentanyl is highly lipophilic, enabling it to cross the blood-brain barrier almost instantaneously; this rapid onset causes severe respiratory depression to set in within minutes, often before bystanders can react (Bird et al. 2023).

Compounding this mechanism is fentanyl’s extreme potency, estimated at 50 to 100 times stronger than morphine and up to 50 times stronger than heroin, where a lethal dose can be as tiny as 2 milligrams. This is directly tied to its unique chemical structure (Figure 1) (Ramos-Matos et al. 2023).

Figure 1: Fentanyl is a synthetic 4-anilidopiperidine derivative and features a flexible, elongated carbon backbone consisting of a central piperidine ring attached to a phenethyl group and an anilide chain (Vardanyan and Hruby 2014).

To understand why fentanyl creates such a powerful cycle of dependency, we have to look at the brain’s mesolimbic reward pathway, specifically the connection between the ventral tegmental area (VTA) and the nucleus accumbens (Volkow et al. 2019). Under normal conditions, GABAergic interneurons in the VTA act as natural brakes to limit dopamine release. However, when fentanyl binds to μ-opioid receptors on these GABA interneurons, it inhibits them (Volkow et al. 2019). With the GABA “brakes” removed, VTA neurons fire uncontrollably, causing a massive, rapid surge of dopamine into the nucleus accumbens (Volkow et al. 2019; Niehaus et al. 2010). This intense dopamine spike reinforces the drug-seeking behaviour by signalling extreme reward to the brain (Volkow et al. 2019). Over time, repeated exposure alters synaptic plasticity and downregulates natural dopamine production, driving severe physical dependence and intense cravings just to feel baseline normal (Niehaus et al. 2010).

In turn, Dilaudid is used in this mesolimbic pathway to safely meet these receptor requirements  (Karamouzian et al. 2023; Roberts and Humphreys 2023; Young et al. 2022). By providing a controlled dose of hydromorphone, participants can manage their dependence and avoid acute withdrawal (H. Canada 2021a). Consequently, individuals experience significantly fewer life-threatening toxicities, leading to a decrease in emergency room visits and hospital admissions (H. Canada 2021b).

Bird, H. Elizabeth, Andrew S. Huhn, and Kelly E. Dunn. 2023. “Fentanyl Absorption, Distribution, Metabolism, and Excretion (ADME): Narrative Review and Clinical Significance Related to Illicitly-Manufactured Fentanyl.” Journal of Addiction Medicine 17 (5): 503–8. https://doi.org/10.1097/ADM.0000000000001185. 

Canada, Health. 2021a. “Safer Supply: Prescribed Medications as a Safer Alternative to Toxic Illegal Drugs.” Service description. July 22. https://www.canada.ca/en/health-canada/services/opioids/responding-canada-opioid-crisis/safer-supply.html. 

Canada, Health. 2021b. “Substance-Related Poisonings and Homelessness in Canada: A Descriptive Analysis of Hospitalization Data.” Datasets. June 23. https://www.canada.ca/en/health-canada/services/opioids/hospitalizations-substance-related-poisonings-homelessness.html. 

Canada, Public Health Agency of. 2019. “Key Findings: Opioid- and Stimulant-Related Harms in Canada — Canada.Ca.” Datasets;statistics;education and awareness. December 11. https://health-infobase.canada.ca/substance-related-harms/opioids-stimulants/. 

Chang, Ji Eun, Zoe Lindenfeld, and Holly Hagan. 2023. “Integrating Harm Reduction into Medical Care: Lessons from Three Models.” Journal of the American Board of Family Medicine : JABFM 36 (3): 449–61. https://doi.org/10.3122/jabfm.2022.220303R3. 

Dhaliwal, Armaan, and Mohit Gupta. 2023. “Physiology, Opioid Receptor.” In StatPearls. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK546642/. 

Garnett, Matthew F., Jodi A. Cisewski, and Farida B. Ahmad. 2026. “Drugs Most Frequently Involved in Drug Overdose Deaths: United States, 2017–2023.” In National Vital Statistics Reports [Internet]. National Center for Health Statistics (US). https://doi.org/10.15620/cdc/174640. 

Herman, Timothy F., Marco Cascella, and Maria Rosaria Muzio. 2024. “Mu Receptors.” In StatPearls. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK551554/. 

Karamouzian, Mohammad, Bijan Rafat, Gillian Kolla, et al. 2023. “Challenges of Implementing Safer Supply Programs in Canada during the COVID-19 Pandemic: A Qualitative Analysis.” International Journal of Drug Policy 120 (October): 104157. https://doi.org/10.1016/j.drugpo.2023.104157. 

Niehaus, Jason L., Manjari Murali, and Julie A. Kauer. 2010. “Drugs of Abuse and Stress Impair LTP at Inhibitory Synapses in the Ventral Tegmental Area.” The European Journal of Neuroscience 32 (1): 108–17. https://doi.org/10.1111/j.1460-9568.2010.07256.x. 

Ramos-Matos, Carlos F., Karlyle G. Bistas, and Wilfredo Lopez-Ojeda. 2023. “Fentanyl.” In StatPearls. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK459275/. 

Roberts, Emmert, and Keith Humphreys. 2023. “‘Safe Supply’ Initiatives: Are They a Recipe for Harm Through Reduced Health Care Input and Supply-Induced Toxicity and Overdose?” Journal of Studies on Alcohol and Drugs 84 (4): 644–47. https://doi.org/10.15288/jsad.23-00054. 

Saunders, Sandy E., David M. Baekey, and Erica S. Levitt. 2022. “Fentanyl Effects on Respiratory Neuron Activity in the Dorsolateral Pons.” Journal of Neurophysiology 128 (5): 1117–32. https://doi.org/10.1152/jn.00113.2022. 

Theriot, Jonathan, Sarah Sabir, and Mohammadreza Azadfard. 2026. “Opioid Antagonists.” In StatPearls. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK537079/. 

Vardanyan, Ruben S., and Victor J. Hruby. 2014. “Fentanyl-Related Compounds and Derivatives: Current Status and Future Prospects for Pharmaceutical Applications.” Future Medicinal Chemistry 6 (4): 385–412. https://doi.org/10.4155/fmc.13.215. 

Volkow, Nora D., Michael Michaelides, and Ruben Baler. 2019. “The Neuroscience of Drug Reward and Addiction.” Physiological Reviews 99 (4): 2115–40. https://doi.org/10.1152/physrev.00014.2018. 

Young, Samantha, Gillian Kolla, Daniel McCormack, et al. 2022. “Characterizing Safer Supply Prescribing of Immediate Release Hydromorphone for Individuals with Opioid Use Disorder across Ontario, Canada.” International Journal of Drug Policy 102 (April): 103601. https://doi.org/10.1016/j.drugpo.2022.103601.